Case Report: Acquired Disseminated BCG in the Context of a Delayed Immune Reconstitution After Hematological

Vincent Gies1,2,3, Yannick Dieudonné1,2, Florence Morel4,5

  • 1Department of Clinical Immunology and Internal Medicine, National Reference Center for Systemic Autoimmune Diseases (CNR RESO), Tertiary Center for Primary Immunodeficiency, Strasbourg University Hospital, Strasbourg, France.

Frontiers in Immunology
|August 20, 2021
PubMed

Insights

Disseminated Bacillus Calmette-Guérin (BCG) infection is rare, typically seen in immunocompromised individuals. This case reveals a severe BCG infection in a patient with hematological malignancy, highlighting risks in secondary immunodeficiency.

Area of Science:

  • Infectious Diseases
  • Immunology
  • Genetics

Background:

  • Disseminated Mycobacterium bovis Bacillus Calmette-Guérin (BCG) infections are uncommon, primarily affecting individuals with inborn errors of immunity (IEI) or acquired immunodeficiency.
  • While secondary BCG infections are documented following intravesical BCG instillation, this case presents a distinct scenario.

Observation:

  • A 48-year-old male with a history of hematological malignancy developed severe disseminated BCG disease.
  • The patient had no history of BCG instillation and no known IEI or defects in the IFNγ pathway.
  • Whole genome sequencing identified the BCG strain as closely related to the M. bovis BCG Tice strain.

Findings:

  • This case demonstrates a severe BCG infection in a patient with secondary immunodeficiency due to hematological malignancy.
  • Genetic analysis of the BCG strain suggests a potential link between the patient's acquired immunodeficiency and the infection.

Implications:

  • Physicians, microbiologists, and pharmacists must consider the risk of acquired disseminated BCG disease in immunocompromised patients.
  • Awareness is crucial for patients undergoing BCG treatment for bladder cancer, especially those with secondary immunodeficiencies.
Abstract